GyroStim: Clinical Evidence in treatment of vestibular dysfunction.
top of page

Clinical evidence in the treatment of vestibular dysfunction

Results indicate that GyroStim therapy can provide results up to 5 times faster than traditional therapies alone for vestibular dysfunction.

Clinical Comparison of GyroStim (GS) With Standard of Care (SOC) to SOC Only for Treatment of Vestibular Dysfunction
 

Vestibular rehabilitation therapy (VRT) is a specialized form of physical therapy (PT) that has been recognized as the SOC for treating vestibular dysfunction for decades. 

 

The data table to the right compares retrospective clinical outcomes for two different treatment strategies for patients with vestibular dysfunction:

  • SOC is clinical data for treatment of vestibular dysfunction consisting of targeted vestibular rehabilitation therapy alone

  • GS + SOC is clinical data for treatment of vestibular dysfunction consisting of standard of care combined with GyroStim therapy.

 

The two patient groups in this comparison consisted of randomly selected patients diagnosed with vestibular dysfunction resulting from either PCS, BPPV, PPPD, BVL, CVA, or MdDS.

All patients in both groups received the same standardized assessments for pre and post intervention utilizing gold standard equipment and methods, including SOT, DHI, ABC, and mDGI. Both groups of patients followed the same protocols for intake, balance education, and training for at-home daily exercise routines.

Prelim data.png

All clinical data was collected by and under the guidance of a DPT at a clinic that specializes in balance disorders and vestibular dysfunction.

 

The data comparison was conducted for both treatment groups to compare the following:

  • difference in pre- and post- objective and subjective balance assessment scores

  • duration of treatment time (days) required to achieve similar rehabilitation scores
     

For both groups, SOC and GS+SOC, four datasets were obtained by determining the difference in pre and post treatment scores for SOT, DHI, ABC, and mDGI. These tests were selected for analysis as they represent commonly used clinical balance assessment techniques. For each data set, normality was tested and assessed utilizing either two tailed, Anderson-Darling or Shapiro-Wilk test with alpha=0.05.

The results indicated p<0.0001 for SOT, DHI, ABC, and mDGI tests, therefore, the comparison demonstrates with high confidence that GyroStim therapy combined with vestibular rehabilitation therapy (GS+SOC) presents a statistically significant improvement over vestibular rehabilitation therapy alone. GyroStim treatment combined with SOC provides for safe and effective treatment that is significantly more efficient with an average reduction in treatment time of approximately 70% than SOC alone.

Research on GyroStim and concussion is underway. Stay up to date on our progress through the FDA process.

What is your primary interest in GyroStim?
badge_IVeDA IAC.png

GyroStim is proud to be a member of  the Vestibular Disorders Association's (VeDA) Industry Advisory Council.

  • Instagram
  • Facebook
  • Twitter
GyroStim logo

GyroStim is FDA-cleared for use in the treatment of balance disorders and vestibular dysfunction. 

GyroStim is a product of UltraThera Technologies, Inc.

and is protected by multiple patents, copyrights, and trademarks.

2 North Cascade Avenue / Suite 1320

Colorado Springs, CO 80903

inquiries@gyrostim.com

719-685-7883 

©2024 UltraThera Technologies, Inc.

bottom of page